Head-to-head · WeighScore
Corsica Health vs FuturHealth
The verdict
Corsica Health takes it — 66.3/100 to 65.6/100, but only just.
Corsica Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Corsica Health is a telehealth platform offering both compounded GLP-1s and brand-name FDA-approved injections through a structured assessment, provider review, and medication flow. FuturHealth is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Corsica Health | FuturHealth |
|---|---|---|
| WeighScore | 66.3/100 | 65.6/100 |
| Grade | C | C |
| Scorecard rank | #188 | #215 |
| Semaglutide | $249/mo (compounded) | $199/mo (compounded) |
| Tirzepatide | $349/mo (compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #188 · C
Strengths
- Public pricing shown for both compounded and brand-name options — a real transparency advantage
- $1,499/mo brand-name Wegovy/Ozempic/Mounjaro is below typical retail cash-pay
- LegitScript Certified
- Clear 3-step intake: Assessment, Provider Review, Receive Medication
- $199/mo compounded semaglutide and $249/mo compounded tirzepatide (3-month plans) are competitively priced
Where it loses points
- Legal entity name and state of incorporation not disclosed on the site
- Pharmacy partner described only as a 'licensed compounding pharmacy,' not named
- Per-state availability not listed publicly
- First-month promotional pricing not disclosed
- Lab-work inclusion not clearly disclosed
Graded #215 · C
Strengths
- LegitScript Certified and HITRUST Certified
- Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
- Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
- Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths
Where it loses points
- Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
- BBB complaints describe recurring charges without medication received — confirm cancellation flow first
- Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
- Pricing not shown until after the qualification questionnaire or portal login
- Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.